Here is the trail to tie it all together. From 8K – January 20,...

Here is the trail to tie it all together.

From 8K – January 20, 2015
On January 15, 2015 Unilife Corporation (“Unilife”) entered into a definitive global strategic agreement with AbbVie Inc. (“AbbVie”) for the customization and supply of its injectable drug delivery systems for use with AbbVie’s drug portfolio.

From the First Qtr 2016 Financial Results – November 9, 2015
This quarter, Unilife delivered to a global biopharmaceutical customer customized electronic reusable auto injectors based on the LISA™ device platform on schedule for use in human factors studies. Unilife will recognize $1.2 million in revenue in the second quarter of fiscal 2016 from the customer for completion of the LISA™ feasibility program in addition to payments received for earlier achieved milestones under the program. The exclusivity period for the LISA™ device platform granted by Unilife under the definitive global strategic agreement signed with the customer on January 15, 2015 commences with Unilife's completion of the deliverables under the feasibility program. The milestones tied to the exclusive period for the Unifill Finesse™ prefilled syringe have also been successfully completed. The parties are also working on agreements for other drug delivery systems, and the relationship between Unilife and the customer continues to be strong.

At a conference in June 2016 AbbVie announced that they had received approval of their new formulation of Humira and their new pen device.